Core Viewpoint - LENZ Therapeutics has successfully launched VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia treatment, generating $1.6 million in net product revenues in the first quarter post-launch, with strong prescriber adoption and positive early refill trends [1][9]. Commercial Launch - VIZZ was first commercially sold in October 2025, with Q4 2025 product revenue of approximately $1.6 million from over 20,000 filled prescriptions [6]. - The company is on track for over 45,000 paid prescriptions from launch through Q1 2026, with over 6,500 unique prescribers in Q4 2025, expected to grow to over 10,000 by Q1 2026 [6][9]. Prescriber Adoption and Marketing Strategy - The early performance of VIZZ is encouraging, with broad prescriber uptake and positive refill dynamics, indicating its best-in-class profile [2]. - The company is expanding its sales force from 88 to 117 territories to enhance engagement with eye care professionals (ECPs) and is implementing targeted consumer campaigns to position VIZZ as a viable alternative to reading glasses [5][2]. Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $292.3 million, which is expected to support operations until achieving positive operating cash flow post-launch [9]. - The net loss for Q4 2025 was $35.9 million, or $1.16 per share, compared to a net loss of $12.7 million, or $0.46 per share, in Q4 2024 [14][28]. International Expansion and Partnerships - LENZ submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ and has established multiple international partnerships, including an exclusive commercialization agreement with Lunatus for the Middle East [15][24]. - The company has also made regulatory submissions in Thailand, Singapore, South Korea, and China for VIZZ [15]. Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [18][19]. - The product is preservative-free and provided in single-dose vials, targeting the treatment of presbyopia, a condition affecting approximately 1.8 billion people globally [24].

Core Viewpoint - LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ, an aceclidine ophthalmic solution, marking a significant step in expanding global access to this treatment for presbyopia [1][3] Group 1: Regulatory Submission and Milestones - The MAA submission to the EMA represents the fifth regulatory submission for VIZZ outside the U.S. [1] - If approved, VIZZ will be available to millions of Europeans suffering from age-related blurry near vision [1][3] - The submission is part of LENZ's strategy to establish VIZZ as a global brand, with ongoing commercialization efforts in various regions including Greater China, South Korea, and the Middle East [3] Group 2: Clinical Data and Efficacy - The MAA is supported by positive results from three Phase 3 CLARITY trials conducted in the U.S., where VIZZ met all primary and secondary endpoints, improving near vision within 30 minutes and lasting up to 10 hours [2] - VIZZ was well tolerated, with no serious treatment-related adverse events reported over 30,000 treatment days across the trials [2] Group 3: Market Opportunity and Company Strategy - Presbyopia affects approximately 1.8 billion people globally, with Europe being a significant market for vision correction products [3] - The company aims to pursue commercialization in Europe through strategic partnerships, complementing existing partnerships in other regions [3][4]

Core Insights - LENZ Therapeutics has launched a consumer campaign called "Make it VIZZable" featuring Sarah Jessica Parker as the brand ambassador for VIZZ, an eye drop solution aimed at treating age-related blurry near vision [3][6] - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is available by prescription [11][12] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [15] - The company is headquartered in San Diego, California, and is establishing international licensing partnerships to expand access to VIZZ [15] Product Details - VIZZ is a once-daily eye drop that improves near vision by creating a pinhole effect through the contraction of the iris sphincter muscle, allowing for better depth of focus without causing a myopic shift [8][11] - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes, lasting up to 10 hours [8] Market Context - Age-related blurry near vision, or presbyopia, affects nearly all individuals over the age of 45, with symptoms becoming pronounced in their mid-40s [10] - The gradual progression of presbyopia often leads to an abrupt need for corrective aids, such as reading glasses, impacting daily life significantly [7][10]

Core Insights - LENZ Therapeutics launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025, marking it as the first and only aceclidine-based eye drop for presbyopia treatment, with broad availability by mid-November 2025 [1][5] - The company reported approximately $1.6 million in net product revenue and over 20,000 prescriptions filled in Q4 2025, indicating strong initial market acceptance [1][7] - More than 6,500 unique eye care professionals (ECPs) prescribed VIZZ, with over 55% prescribing it multiple times, reflecting early confidence in the product [2][7] Commercial Highlights - The first commercial sale of VIZZ occurred in October 2025, with full multi-channel access established through e-pharmacy and nearly all retail pharmacies by mid-November 2025 [7] - The rapid uptake by prescribing ECPs is notable, with over 6,500 unique ECPs participating in the prescription process [7] Corporate Updates - In January 2026, LENZ announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East, which includes upfront, regulatory, and commercial milestone payments, along with a significant revenue share [4] - This partnership represents the fourth commercialization agreement for VIZZ outside the United States, indicating the company's strategy to expand its international presence [4] Product Information - VIZZ is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [9] - The product is indicated for age-related blurry near vision (presbyopia) in adults, a condition affecting approximately 1.8 billion people globally [5][10]

Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]

Core Insights - Lotus Pharmaceutical has submitted a New Drug Application (NDA) for VIZZ in South Korea, marking the second regulatory submission for the drug outside the U.S. [1] - The NDA submission is backed by positive results from three Phase 3 studies in the U.S., demonstrating VIZZ's effectiveness in improving near vision [2] - Under the licensing agreement, LENZ Therapeutics stands to receive up to $125 million in milestone payments and royalties from future sales of VIZZ [3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ, the first FDA-approved aceclidine-based eye drop for presbyopia, which affects approximately 1.8 billion people globally [10] - Lotus Pharmaceutical, founded in 1966, is an international pharmaceutical company with a strong R&D and manufacturing platform, certified by major regulatory authorities [11] Product Information - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free [6] - The drug is indicated for the treatment of age-related blurry near vision (presbyopia) in adults [7] Market Context - Presbyopia affects nearly all individuals over the age of 45, with significant implications for daily activities and quality of life [5] - The NDA submission in South Korea is part of a broader strategy to expand VIZZ's market presence in Southeast Asia, including countries like Thailand, Vietnam, and Malaysia [3]

Core Insights - LENZ Therapeutics, Inc. has received FDA approval for VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia, marking it as the first and only aceclidine-based eye drop approved for this condition [1][5][17] - The commercial launch of VIZZ began in October 2025, with broad availability expected by mid-Q4 2025 [1][5] - The company has partnered with Sarah Jessica Parker for a direct-to-consumer campaign, set to launch in Q1 2026 [1][2][5] Commercial Highlights - Over 2,500 Eye Care Professionals (ECPs) have prescribed VIZZ, with 40% of them prescribing multiple times, leading to over 5,000 prescriptions filled by October 2025 [1][2][5] - Awareness of VIZZ among ECPs reached 90% in October 2025, supported by extensive marketing efforts including 17,000 unique ECPs detailed and over 5 million digital campaign impressions [5] - The company has provided nearly 70,000 product samples to approximately 7,000 ECP offices, contributing to increased confidence in prescribing VIZZ [5] Financial Overview - As of September 30, 2025, the company reported pro forma cash, cash equivalents, and marketable securities of approximately $324.0 million, which is expected to support operations until post-launch positive cash flow [1][6] - Selling, General and Administrative (SG&A) expenses increased significantly to $27.6 million for Q3 2025, compared to $6.5 million in Q3 2024, primarily due to increased personnel and marketing expenses [7] - Research and Development (R&D) expenses decreased to $3.8 million for Q3 2025, down from $6.5 million in Q3 2024, reflecting the completion of clinical trials [8] Net Loss - The net loss for the three months ended September 30, 2025, was $16.7 million, compared to a net loss of $10.2 million during the same period in 2024 [9][22] - For the nine months ended September 30, 2025, the net loss was $46.2 million, compared to $37.1 million in the same period in 2024 [9][22]

Core Viewpoint - LENZ Therapeutics has launched VIZZ, the first FDA-approved aceclidine-based eye drop for treating presbyopia, which affects approximately 128 million adults in the U.S. The product is expected to be commercially available by mid-Q4 2025 [1][7]. Product Overview - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to improve near vision for up to 10 hours and is administered as a once-daily eye drop [3][4]. - The mechanism of action involves a predominantly pupil-selective miotic effect, contracting the iris sphincter muscle to create a pinhole effect that enhances depth of focus without causing a myopic shift [1][4]. Clinical Efficacy - In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes of application, with effects lasting up to 10 hours [1][4]. Market Potential - Presbyopia is a common age-related condition impacting nearly all individuals over 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [2][5]. - The global market for presbyopia treatments is significant, with an estimated 1.8 billion people affected worldwide [7]. Company Strategy - LENZ Therapeutics is focused on commercializing VIZZ in the U.S. and establishing international licensing partnerships to expand global access [7].

Core Viewpoint - LENZ Therapeutics is focused on the commercialization of VIZZ™, the first FDA-approved aceclidine-based eye drop for treating presbyopia, and will participate in several upcoming investor and medical conferences to present VIZZ [1][11]. Company Information - LENZ Therapeutics is headquartered in San Diego, California, and is dedicated to providing access to VIZZ globally through licensing partnerships [11]. - The company is targeting a significant market, with presbyopia affecting approximately 1.8 billion people worldwide and 128 million in the United States [11]. Product Details - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [7]. - The product works by causing contraction of the iris sphincter muscle, creating a pinhole effect that enhances depth of focus [7]. Upcoming Conferences - LENZ Therapeutics will participate in several conferences, including: - Citi's 2025 BioPharma Back to School Conference on September 2-3, 2025, in Boston, MA [2]. - Cantor Global Healthcare Conference on September 4, 2025, in New York City, NY [2]. - H.C. Wainwright 27 Annual Global Investment Conference on September 9, 2025, in New York City, NY [2]. - Morgan Stanley 23 Annual Global Healthcare Conference on September 10, 2025, in New York City, NY [3]. - Academy 2025 on October 8-9, 2025, in Boston, MA, featuring presentations on the efficacy of VIZZ [4].

Core Viewpoint - LENZ Therapeutics has received FDA approval for VIZZ, the first aceclidine-based eye drop for treating presbyopia, which affects approximately 128 million adults in the U.S. This product is expected to be available in the U.S. by October 2025, with a once-daily dosing regimen that provides near vision improvement for up to 10 hours [1][2][12]. Group 1: Product Information - VIZZ (aceclidine ophthalmic solution) 1.44% is designed to restore clear near vision for up to 10 hours and is preservative-free, provided in single-dose vials [8][9]. - The mechanism of action involves contracting the iris sphincter muscle to create a pinhole effect, enhancing depth of focus without causing a myopic shift [2][8]. - The FDA approval was based on three Phase 3 studies, demonstrating significant near vision improvement within 30 minutes and lasting up to 10 hours [3][4]. Group 2: Clinical Trials and Efficacy - In the CLARITY 1 and CLARITY 2 studies, VIZZ met all primary and secondary endpoints for near vision improvement, with consistent results across both trials [4]. - The trials involved 466 participants in CLARITY 1 and CLARITY 2, and 217 participants in CLARITY 3, which assessed long-term safety over six months [3][4]. - VIZZ was well-tolerated, with no serious treatment-related adverse events reported during over 30,000 treatment days [4][11]. Group 3: Market Impact and Future Plans - The approval of VIZZ is seen as a transformative advancement in treatment options for presbyopia, potentially becoming the standard of care for optometrists and ophthalmologists [2][3]. - The company plans to initiate direct-to-eye care professional sales and marketing activities immediately following the approval [1][2]. - LENZ Therapeutics aims to establish international licensing partnerships to expand access to VIZZ globally [12].